Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36.

View in: PubMed

subject areas

Acute Disease
Adult
Antineoplastic Combined Chemotherapy Protocols
Chromosome Aberrations
Chromosome Inversion
Chromosomes, Human
Cytarabine
Daunorubicin
Disease-Free Survival
Follow-Up Studies
Humans
Incidence
Karyotyping
Leukemia, Myeloid
Life Tables
Prospective Studies
Recurrence
Remission Induction
Risk Factors
Survival Analysis
Translocation, Genetic
Treatment Outcome
Trisomy

authors with profiles

Richard A. Larson